Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD1 | P21728 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD5 | P21918 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888496 | 1.00 | DRD2 (0.51) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL12718120 | 1.00 | DRD2 (0.51) | DRD2DRD1DRD4DRD5DRD3 | |
| Ammonia Solution, Strong SCHEMBL10418233 | 0.98 | DRD2 (0.50) | DRD2DRD1DRD4DRD5DRD3 | |
| Hydrochloric Acid SCHEMBL30330522 | 0.98 | DRD2 (0.50) | DRD2DRD1DRD4DRD5DRD3 | |
| Acetic Acid SCHEMBL29252371 | 0.89 | KDM4E (0.57) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL205774 | 0.88 | HRH3 (0.49) | KDM4EALDH1A1LMNAHRH3 | |
| SCHEMBL29252629 | 0.88 | KDM4E (0.49) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL10130206 | 0.86 | — | — | |
| SCHEMBL10130175 | 0.86 | — | — | |
| SCHEMBL806007 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4038377-A1 | ORGANIC ELECTROCHEMICAL TRANSISTOR FOR BIOLOGICAL ELEMENT | Omini (FR) | 2022-08-10 | — | — | EP | claimed |
| WO-2024038378-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-02-22 | — | — | WO | disclosed |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| WO-2023093728-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2023009618-A1 | BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING | EPIRIUM BIO, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| WO-2008133975-A1 | MULTI-RING COMPOUNDS AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008012413-A2 | PYRIMIDINONE DERIVATIVES AND THEIR USE AS A DRUG | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUE (S.C.R.A.S.) (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | TIBOTEC BVBA (BE) | 2007-10-11 | — | — | US | disclosed |
| WO-2007098086-A2 | HYDROXYPIPERIDINE DERIVATIVES AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2007-08-30 | — | — | WO | disclosed |
| WO-2005023808-A2 | PROCESS FOR THE PREPARATION OF RENZAPRIDE AND INTERMEDIATES THEREOF | ALIZYME THERAPEUTICS LIMITED (GB) | 2005-03-17 | — | — | WO | disclosed |
| US-4910270-A | Curable resin | KOEI CHEMICAL CO., LTD. (JP) | 1990-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322761-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, LYN | DRD2 4082/4885DRD1 3994/4885DRD4 4397/4885 |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | DRD2 4610/4885DRD1 4550/4885DRD4 4603/4885 |
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | DRD2 4299/4885DRD1 4048/4885DRD4 2770/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | DRD2 4565/4885DRD1 4438/4885DRD4 4322/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | DRD2 4610/4885DRD1 4550/4885DRD4 4603/4885 |
| US-20070238727-A1 | 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals | NR5A2, NR5A1, NR4A1 | DRD2 373/4885DRD1 330/4885DRD4 362/4885 |
| US-11858931-B2 | Amino acid compounds with unbranched linkers and methods of use | ITGA2B, ITGB6, ITGB1 | DRD2 3214/4885DRD1 3908/4885DRD4 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.